Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
“MINDCURE is actively on course, further advancing our proprietary synthesis processes, and developing a series of mixtures from our fully synthetic ibogaine, serving as a key catalyst and important step in our pre-clinical development program towards Good Manufacturing Practice (“GMP”) certification of ibogaine and the ability to scale and manufacture a global supply of fully synthetic ibogaine for research partners,” said MINDCURE’s President and CEO Kelsey Ramsden
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
In addition to the election of all nominees listed as Directors in the Management Information Circular, Numinus shareholders approved all other resolutions placed before the Meeting, including setting the number of directors of the Company at five, the appointment of Davidson & Company LLP as auditors for the Company for the ensuing year and approval of the Omnibus Equity Incentive Plan
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
The project, led by Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, Vocan CEO, had Vocan’s team of scientists optimized DNA sequences that can produce enzymes replicating the biosynthetic pathways used by Psilocybes mushrooms, combined with enhanced enzymes from bacteria and animals.
PharmAla Biotech contracts with InterVivo Solutions to validate novel MDMA analogs
“PharmAla’s goal is to create novel drugs with improved toxicology profiles, and to expand use cases and indications for these drugs. PharmAla’s ABA series of drug candidates are based on a molecule in the MDXX class which is not scheduled as a controlled substance in Canada,” said Nick Kadysh, PharmAla’s CEO. “In InterVivo Solutions, we have found an excellent research partner to fast-track the research to select the most promising drug in the ABA series, and bring it forward to the Clinical phase.”
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
- Record high revenue of $2,452,540, +32% over the previous quarter
- Opened new outpatient clinic located in downtown Salt Lake City
- Strong pipeline of clinical trials for psychedelics and mental health treatments
- In January 2022, successfully closed the acquisition of an Arizona-based mental health practice, adding two additional clinics, and closed a $5,000,000 institutional private placement
Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes
Revitalist and PharmaTher have entered into a collaboration agreement with a focus on developing unique ways to scientifically advance the utilization of ketamine in more robust and safer ways. Also, PharmaTher will seek to engage Revitalist’s ketamine clinics for future clinical studies with KETARX™.
